Ann: Brain Injury Program GLP Studies Further Update, page-36

I really sit down and look at what’s out there right now in this space and there is huge opportunity for NYR to become a 120 million market cap leading into phase 2 like AGN. NYR will be doing TBI and stroke plus as a drug molecule and not a peptide can be made in a variety of formulations from tablets to nasal sprays and puffers. Company is currently at a 9 million market cap and with rebates coming in will be fully funded to get the drug to phase 2. The main thing right now is the safety results coming over the next few weeks plus Walter Reed success of any sort will provide the company with huge opportunities for non dilutive funding for phase 2.

So it’s all about safety. Efficacy and comparing this to different drugs, you can’t because nothing is approved out there for these conditions via the FDA. So the potential upside is exponential on safety success because the drug works